{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: Mexico Medical Distribution news", "home_page_url": "https://sharemaestro.com/newsreel/mx/healthcare/medical-distribution/", "feed_url": "https://sharemaestro.com/newsreel/mx/healthcare/medical-distribution/feed.json", "description": "Latest Medical Distribution company headlines from Mexico, newest first, with source links and direct routes to company research and sentiment.", "language": "en", "items": [{"id": "source:b74be96cd5f5efc27a1975a810d23f471308703fbbcf5d6071d20fcf9d9547a4", "url": "https://finance.yahoo.com/m/c936783e-315d-3ad2-9bd9-efb645974d94/s%26p-500-medical-stocks%3A-three.html", "external_url": "https://finance.yahoo.com/m/c936783e-315d-3ad2-9bd9-efb645974d94/s%26p-500-medical-stocks%3A-three.html", "title": "S&P 500 Medical Stocks: Three Trade Near Buy Points; One Rallies Despite Mixed Results", "content_text": "S&P 500 drug distributor Cardinal Health easily topped fiscal fourth-quarter earnings forecasts despite a revenue shortfall. Rival McKesson, which whipsawed after its earnings report last week, has climbed back near a buy point. Cencora, another big S&P 500 drug distributor, also is near a buy point, but MCK stock may be the strongest of the three. Continue Reading", "date_published": "2026-08-11T13:16:16+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "MCK"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MCK", "name": "McKesson Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/0690fb95-d935-4df1-aa4f-b67259d735cf/"}]}}, {"id": "source:9ddd761135a42644a06e16f5f557780ced646dba615b813bc2fbaca4a0bbf881", "url": "https://finance.yahoo.com/healthcare/articles/qdel-q2-earnings-revenues-beat-172900707.html", "external_url": "https://finance.yahoo.com/healthcare/articles/qdel-q2-earnings-revenues-beat-172900707.html", "title": "QDEL Q2 Earnings & Revenues Beat Estimates, 2026 Guidance Lowered", "content_text": "QuidelOrtho Corporation QDEL delivered adjusted earnings per share (EPS) of 13 cents in second-quarter 2026, up 8.3% year over year. The figure beat the Zacks Consensus Estimate by 425%. The adjustments include expenses related to the amortization of intangibles, acquisition and integration costs, among others. GAAP loss per share for the quarter was $1.36 compared with the year-earlier loss of $3.77. QDEL's Revenues in Detail QuidelOrtho registered revenues of $630.9 million in the second quarter of 2026, which increased 2.8% year over year on a reported basis and 1.9% at constant exchange rate (CER). The figure surpassed the Zacks Consensus Estimate by 2.65%. In the second quarter, Respiratory revenues were $47.9 million (up 2.6% on a reported basis and 2.5% at CER), while Non-Respiratory revenues were $583 million (up 2.8% on a reported basis and 1.8% at CER). QuidelOrtho's Business Units in Detail QuidelOrtho derives revenues from five business units \u2014 Labs, Immunohematology, Donor Screening, Point of Care and Molecular Diagnostics. As a result of the wind-down of the U.S. Donor Screening portfolio, the previously reported Transfusion Medicine business unit is now presented in its two product categories \u2014 Immunohematology and Donor Screening. In the second quarter, Labs revenues were $382.9 million, up 3.6% on a reported basis and 2.4% at CER. Immunohematology revenues were $134.2 million in the second quarter, up 1.4% and 0.7% on a reported basis and at CER, respectively. Donor Screening revenues were $4 million in the second quarter, down 69.9% on a reported basis and 69.5% at CER. Point of Care revenues amounted to $108.2 million in the second quarter, reflecting increases of 16.3% on a reported basis and 15.7% at CER. Molecular Diagnostics revenues totaled $1.6 million in the second quarter, down 71.4% on a reported basis and 72% at CER. QDEL's Geographical Distribution Geographically, QuidelOrtho derives revenues from North America, Europe, the Middle East and Africa (EMEA), China, Latin America and Japan and other Asia-Pacific markets (JPAC). Revenues from North America amounted to $327.4 million, reflecting an increase of 5.4% on a reported basis and 5.8% at constant exchange rate (CER). EMEA revenues amounted to $91.2 million, reflecting an increase of 4.5% on a reported basis and 1.5% at CER. Revenues from China amounted to $67.8 million, reflecting a decrease of 18.7% on a reported basis and 23.3% at CER. Revenues from JPAC amounted to $74.3 million, reflecting an uptick of 2.9% on a reported basis and 10.5% at CER. Story Continues Revenues from Latin America amounted to $70.2 million, reflecting an uptick of 16.4% on a reported basis and 7.8% at CER. QuidelOrtho Corporation Price, Consensus and EPS SurpriseQuidelOrtho Corporation Price, Consensus and EPS Surprise QuidelOrtho Corporation price-consensus-eps-surprise-chart | QuidelOrtho Corporation Quote QuidelOrtho's Margin Trend In the quarter under review, QuidelOrtho's adjusted gross profit declined 0.2% year over year to $279.9 million. The adjusted gross margin contracted 130 basis points (bps) to 44.4%. Adjusted selling, marketing and administrative expenses increased 2% year over year to $174 million. Adjusted research and development expenses remained flat year over year at $45 million. Adjusted operating expenses of $219 million increased 2% year over year. Adjusted operating profit totaled $60.2 million, flat year over year. Adjusted operating margin in the second quarter contracted 30 bps to 9.5%. QDEL's Financial Position QuidelOrtho exited the second quarter of 2026 with cash and cash equivalents of $123.4 million compared with $140.4 million at the end of the first quarter of 2026. Total debt (including short-term debt) at the end of second-quarter 2026 was $2.89 billion compared with $2.69 billion at the end of the first quarter of 2026. Cumulative net cash used by operating activities at the end of the second quarter was $143.6 million, against ne", "date_published": "2026-08-10T17:29:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "MCK"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MCK", "name": "McKesson Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/0690fb95-d935-4df1-aa4f-b67259d735cf/"}]}}, {"id": "source:eea56fbe5b3a2fa7d2a1a634e26d8e932034e8a6762f085c7c252d962bfd3312", "url": "https://finance.yahoo.com/healthcare/articles/integer-holdings-q2-earnings-revenues-172700785.html", "external_url": "https://finance.yahoo.com/healthcare/articles/integer-holdings-q2-earnings-revenues-172700785.html", "title": "Integer Holdings Q2 Earnings & Revenues Top Estimates, Margins Decline", "content_text": "Integer Holdings Corporation ITGR delivered adjusted earnings per share (EPS) of $1.60 in the second quarter of 2026, up 3.2% year over year. The figure beat the Zacks Consensus Estimate by 15.9%. The adjustments include expenses related to the amortization of intangible assets and restructuring and restructuring-related charges, among others. GAAP EPS for the quarter was 69 cents, down 33.7 % from the prior-year quarter. ITGR's Revenues in Detail Integer Holdings registered revenues of $464.1 million in the second quarter, down 2.6% year over year. However, the figure topped the Zacks Consensus Estimate by 2.2%. Organically, revenues decreased 1.5%. Integer Holdings' Q1 Segmental Analysis Integer Holdings operates through three product lines \u2014 Cardio and Vascular (C&V); Cardiac Rhythm Management & Neuromodulation (CRM&N) and Other Markets. In the second quarter of 2026, the C&V product line generated revenues of $280.3 million, down 2.3% year over year. Organically, sales declined 2.5%. The decrease primarily reflected the previously communicated impact from two new Electrophysiology products. The CRM&N product line reported revenues of $173.7 million, up 1% year over year. Organic sales also increased 1%. Growth in the product line was partially offset by the previously communicated impact from one new Neuromodulation product. Revenues from Other Markets totaled $10.1 million, down 42.8% from $17.6 million in the prior-year quarter. Organically, sales declined 13.5%. The sharp reported decrease primarily reflected Integer Holdings' strategic exit from the Portable Medical business. ITGR's Margin Analysis Integer Holdings generated a gross profit of $112.9 million in the second quarter, down 12.6% year over year. The gross margin in the reported quarter contracted about 280 basis points (bps) to 24.3% from 27.1% in the prior-year period. Selling, general and administrative expenses were $57.7 million, up 9% year over year. Research, development and engineering costs were $11.3 million in the quarter, down 20.8% year over year. Total operating expenses of $78.4 million increased 12.3% year over year. Adjusted operating profit totaled $73 million, reflecting a decline of 10.2% from the prior-year quarter. Adjusted operating margin in the second quarter contracted about 130 bps to 15.7% from 17.1% a year ago. Integer Holdings' Financial Position Integer Holdings exited the second quarter of 2026 with cash and cash equivalents of $21.4 million compared with $8.1 million at the first-quarter end. Total debt (including the current portion) at the end of second-quarter 2026 was $1.24 billion, down from $1.25 billion at the end of the first quarter. Story Continues Cumulative cash flow from operating activities at the end of second-quarter 2026 was $84.4 million compared with $75.1 million a year ago. Integer Holdings Corporation Price, Consensus and EPS SurpriseInteger Holdings Corporation Price, Consensus and EPS Surprise Integer Holdings Corporation price-consensus-eps-surprise-chart | Integer Holdings Corporation Quote Integer Holdings' KKR Deal Reshapes the Outlook Integer Holdings and KKR separately announced a definitive agreement under which an affiliate of KKR-managed investment funds will acquire all outstanding Integer shares for $127 per share in cash. The transaction carries an enterprise value of $5.7 billion. Given the pending transaction, Integer Holdings withdrew its previously issued financial outlook. The company also canceled its previously scheduled second-quarter earnings conference call and webcast. Wrapping Up Integer Holdings exited the second quarter of 2026 with a mixed performance. Revenues declined year over year, reflecting continued pressure from previously communicated product-related headwinds and the strategic exit from Portable Medical. However, adjusted EPS increased 3.2%, supported by a relatively stable adjusted net income despite the softer top line. On the product-line front, performance remain", "date_published": "2026-08-10T17:27:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "MCK"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MCK", "name": "McKesson Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/0690fb95-d935-4df1-aa4f-b67259d735cf/"}]}}, {"id": "source:aee2b7d5095f7c792c4d32b8ddfd7cca1d816946bccddcaa95ac2ca41f113624", "url": "https://finance.yahoo.com/healthcare/articles/mckesson-q1-earnings-call-highlights-180351797.html", "external_url": "https://finance.yahoo.com/healthcare/articles/mckesson-q1-earnings-call-highlights-180351797.html", "title": "McKesson Q1 Earnings Call Highlights", "content_text": "Key Points Interested in McKesson Corporation? Here are five stocks we like better. McKesson raised its fiscal 2027 outlook after a stronger-than-expected first quarter, with revenue up 8% to $105.4 billion and adjusted EPS up 20% to $9.93. The company now expects adjusted EPS of $44.20 to $45.00 for the full year. North American Pharmaceutical led results, while GLP-1 distribution revenue surged 24% year over year to $15 billion. Oncology & Multispecialty and Prescription Technology Solutions also delivered double-digit operating-profit growth. McKesson advanced the planned separation of its ", "date_published": "2026-08-08T18:03:51+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MCK"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MCK", "name": "McKesson Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/0690fb95-d935-4df1-aa4f-b67259d735cf/"}]}}, {"id": "source:8e8a556fc74e94d40982edd16b1c00049d34b139eead8b2dcec7effd35a7d1e5", "url": "https://finance.yahoo.com/markets/stocks/articles/higher-sales-lower-eps-guidance-091137498.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/higher-sales-lower-eps-guidance-091137498.html", "title": "How Higher Sales, Lower EPS And New Guidance At McKesson (MCK) Has Changed Its Investment Story", "content_text": "On August 5, 2026, McKesson Corporation reported first-quarter fiscal 2027 results showing sales of US$105.38 billion, higher than a year earlier, while net income and earnings per share from continuing operations declined year-on-year. Alongside these results, McKesson completed a large portion of its long-running share repurchase program and raised adjusted earnings guidance, highlighting management's confidence in specialty and oncology growth, technology and AI investments, and the company's ability to return cash to shareholders. Next, we'll examine how McKesson's upgraded earnings guidan", "date_published": "2026-08-08T09:11:37+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MCK"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MCK", "name": "McKesson Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/0690fb95-d935-4df1-aa4f-b67259d735cf/"}]}}, {"id": "source:56de1a9b1038873ed40601bd3351f32b984fec6a2054a3eb9e534589cce5e6e9", "url": "https://finance.yahoo.com/healthcare/articles/pharma-specialty-demand-boost-cardinal-182000838.html", "external_url": "https://finance.yahoo.com/healthcare/articles/pharma-specialty-demand-boost-cardinal-182000838.html", "title": "Will Pharma and Specialty Demand Boost Cardinal Health's Q4 Results?", "content_text": "Cardinal Health CAH is scheduled to report fourth-quarter fiscal 2027 results on Aug. 11, before market open. The Zacks Consensus Estimate for sales is pegged at $65.61 billion, implying 9.1% year-over-year growth. The bottom line estimate is pinned at $2.42, suggesting growth of 16.4%. The EPS estimates have remained stable over the past seven days. The company delivered an earnings surprise of 13.21% in the last reported quarter. Its earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 10.27%. What the Zacks Model Unveils Our proven model predicts an earnings beat for Cardinal Health this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here, as you will see below. Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate ($2.45 per share) and the Zacks Consensus Estimate is +1.24% for CAH. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter. Zacks Rank: The company carries a Zacks Rank #2 at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Cardinal Health, Inc. Price and EPS SurpriseCardinal Health, Inc. Price and EPS Surprise Cardinal Health, Inc. price-eps-surprise | Cardinal Health, Inc. Quote Factors Likely to Have Driven Q4 Performance Cardinal Health is expected to have delivered robust performance during the fourth quarter of fiscal 2026, supported by sustained momentum in its Pharmaceutical and Specialty Solutions business and continued strength across its higher-margin growth businesses. Pharmaceutical demand is likely to have remained healthy across specialty, branded, generic and consumer health products. The ongoing expansion of the company's specialty platform, including Solaris integration and its Specialty Alliance physician network, should have continued to boost revenue growth. Management had previously indicated that specialty revenues were growing at more than 20% and were expected to exceed $50 billion in fiscal 2026, suggesting that the segment likely remained a key driver of earnings. Within the Pharmaceutical segment, profit growth is expected to have continued outpacing revenue growth, supported by favorable branded and specialty product contributions, resilient generic market dynamics, and preserved economics on distribution contracts despite Inflation Reduction Act (IRA)-related pricing changes. However, revenue growth may have remained moderate due to lower wholesale acquisition cost (WAC) pricing under the IRA, slower GLP-1 growth normalization and ongoing loss-of-exclusivity transitions. Story Continues The Global Medical Products and Distribution (GMPD) segment is likely to have remained a mixed performer. Continued growth in Cardinal Health-branded products, cost optimization initiatives and operational simplification should have supported underlying execution, although tariffs, selective customer volume losses and inflationary pressures on certain product categories may have continued weighing on profitability. Meanwhile, the company's Other businesses \u2014 At-Home Solutions, Nuclear and Precision Health Solutions, and OptiFreight Logistics \u2014 are expected to have sustained their robust growth trend, aided by strong demand, theranostics expansion, ADS integration synergies and logistics volume gains. Continued investments in technology, automation and distribution infrastructure are also likely to have supported long-term growth. Cardinal Health's disciplined capital allocation, ongoing share repurchases and resilient operating execution are expected to have supported another quarter of healthy earnings growth despite persistent pricing and tariff-related headwinds. CAH Share Price Performance In the year-to-date period, CAH shares have rallied 15.6%, outperforming its industry's 4.8% growth over the same p", "date_published": "2026-08-07T18:20:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "MCK"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MCK", "name": "McKesson Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/0690fb95-d935-4df1-aa4f-b67259d735cf/"}]}}, {"id": "source:220f3a1be480ca0ded787581e0fc6502214d3ff3ae268c27cbbe83698f16df48", "url": "https://finance.yahoo.com/healthcare/articles/10x-genomics-q2-earnings-revenues-175700399.html", "external_url": "https://finance.yahoo.com/healthcare/articles/10x-genomics-q2-earnings-revenues-175700399.html", "title": "10x Genomics Q2 Earnings & Revenues Beat Estimates, Gross Margin Up", "content_text": "10x Genomics TXG reported a second-quarter 2026 loss of 14 cents per share against earnings of 28 cents in the year-ago quarter, representing a 150% year-over-year decline. Still, the figure beat the Zacks Consensus Estimate of a loss of 23 cents by 38.1%. Revenues of $151 million declined 12.6% year over year but surpassed the Zacks Consensus Estimate of $146.9 million by 2.8%. Excluding non-recurring patent litigation settlement revenues in both periods, revenues increased 3%. Shares of TXG lost 5% in yesterday's after-market trading. The company's shares have surged 194% in the year-to-date period against the industry's decrease of 6.5%. However, the broader S&P 500 Index has increased 12.4% in the same time frame.Zacks Investment Research Image Source: Zacks Investment Research TXG's Consumables Business Maintains Momentum Products and services revenues totaled $149.1 million, up 2.7% year over year. Total consumables revenues were $130.8 million, with Single Cell consumables increasing 3.1% year over year to $88.5 million and Spatial consumables rising 16.2% to $42.3 million. Total instrument revenues declined 47.2% year over year to $7.7 million. Single Cell instrument revenues fell 46.1% year over year to $3.1 million, while Spatial instrument revenues dropped 47.8% to $4.6 million. Management noted that the decline in Spatial instruments reflected customers moderating purchases of existing products ahead of the Atera launch. Services revenues increased 26% year over year to $10.7 million. 10x Genomics' Regional Performance Stays Mixed Total Americas revenues were $85 million, down 19.9% from the prior-year quarter. However, excluding non-recurring license and royalty revenues in both periods, Americas revenues increased 6% year over year, indicating better underlying performance than the reported comparison suggests. EMEA revenues rose 15.1% year over year to $39.9 million. Asia-Pacific revenues declined 18.7% year over year to $26 million. Management noted that the prior-year Asia-Pacific results benefited from roughly $4 million of purchasing activity pulled forward in China ahead of potential tariff changes. TXG's Margin Trend In the quarter under review, TXG's gross profit declined 10.1% year over year to $112.5 million. However, the gross margin expanded 200 basis points (bps) to 74%, primarily driven by lower manufacturing costs, including $2.6 million of tariff refunds and lower inventory write-downs. Selling, general and administrative expenses increased 5.7% year over year to $78.7 million. Research and development expenses declined 7.2% year over year to $56.8 million. Total operating expenses of $132.1 million increased 39.1% year over year, mainly due to a lower gain on settlement compared with the prior-year quarter. Excluding settlement gains, operating expenses were approximately flat year over year. Story Continues Total operating loss was $19.6 million against an operating income of $30.1 million in the year-ago quarter. TXG's Financial Position TXG exited the second quarter of 2026 with cash, cash equivalents and marketable securities of $552 million, up from $539.8 million at the end of the first quarter of 2026. Importantly, the company ended the quarter with no debt on its balance sheet, underscoring a solid solvency position. 10x Genomics Raises Its 2026 Revenue Outlook The company raised its 2026 revenue guidance to $610 million-$630 million from the prior range of $600 million-$625 million. Excluding non-recurring patent litigation settlement revenues in both 2026 and 2025, the updated outlook represents growth of 2% to 5% over 2025. Management attributed the increase to first-half performance and the $1.6 million of settlement revenue recognized during the second quarter. The outlook assumes that the broader academic funding environment remains roughly consistent with recent conditions, leaving potential improvement in funding outside the company's current guidance assumptions. 10x Genomics Pri", "date_published": "2026-08-07T17:57:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "MCK"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MCK", "name": "McKesson Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/0690fb95-d935-4df1-aa4f-b67259d735cf/"}]}}, {"id": "source:0a037715649a67c7f32ea299dbfdd6eda04505b686e1af1f202ebf7d7725fe8a", "url": "https://finance.yahoo.com/markets/stocks/articles/rigetti-q2-earnings-miss-estimates-175500672.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/rigetti-q2-earnings-miss-estimates-175500672.html", "title": "Rigetti Q2 Earnings Miss Estimates on Higher Costs, Revenue Beat", "content_text": "Rigetti Computing RGTI reported second-quarter 2026 adjusted loss per share of 5 cents, wider than 4 cents in the prior-year quarter. The metric also missed the Zacks Consensus Estimate of earnings by 66.7%. GAAP loss per share in the reported quarter was 16 cents compared with 13 cents in the prior-year quarter. The company reported total revenues of $5.1 million, up 185.3% year over year. The top line surpassed the Zacks Consensus Estimate by 4.68%. Shares of this company lost 3.5% in yesterday's after-market trading. The company's shares have plunged 22.6% in the year-to-date period compared with the industry's decrease of 5.8%. However, the broader S&P 500 Index has increased 12.4% in the same time frame.Zacks Investment Research Image Source: Zacks Investment Research Rigetti's Q2 Revenue Growth Rigetti's second-quarter 2026 revenues benefited from growing demand for its on-premises quantum computing systems, including Novera-based deployments, along with broader engagement across government, academic and commercial customers. RGTI's Margin Trend In the quarter under review, RGTI's gross profit surged 286.6% year over year to $2.2 million. The gross margin expanded roughly 1,120 basis points to 42.6%. Selling, general and administrative expenses increased 37.5% year over year to $9.5 million. Research and development expenses rose 53.3% year over year to $20.7 million. Total operating expenses of $30.3 million increased 47.9% year over year. Operating loss for the quarter under review totaled $28.1 million compared with $19.9 million in the prior-year quarter. RGTI's Financial Position RGTI exited the second quarter of 2026 with cash, cash equivalents and short-term available-for-sale investments of $393.7 million compared with $418.2 million at the end of the first quarter of 2026. The company ended the quarter with no debts on its balance sheet. Cumulative net cash provided by operating activities at the second-quarter end was $14.9 million against net cash used in operating activities of $369.7 million a year ago. Wrapping Up Rigetti exited second-quarter 2026 with mixed results, wherein revenues surpassed the Zacks Consensus Estimate, but earnings missed the same. Strong year-over-year revenue growth, driven by on-premises Novera QPU and system deliveries, was encouraging. Customer engagement also broadened across government, academic and commercial markets. Rigetti continued to fulfill on-premises system commitments, including its 108-qubit program for C-DAC in India. The company also expanded its collaboration with Hewlett Packard Enterprise and the Pittsburgh Supercomputing Center. A 9-qubit Novera system is set to be deployed at PSC's TangleLab testbed to support hybrid quantum-classical computing research. Story Continues On the technology front, Rigetti continued to advance its Cepheus platform. Cepheus-1-108Q operated at approximately 99.1% median two-qubit gate fidelity, 99.9% median single-qubit gate fidelity and gate speeds of about 60 nanoseconds. The company also demonstrated median two-qubit gate fidelities of 99.8% and 99.6% on its 9-qubit and 36-qubit systems, respectively. Rigetti remains focused on improving coherence time through chip design, fabrication, materials and process enhancements. Its longer-term roadmap targets roughly 1,000 qubits, 99.9% two-qubit gate fidelity and gate speeds below 50 nanoseconds. The Department of Commerce letter of intent for up to $100 million of potential funding could further support R&D aimed at addressing scaling challenges in superconducting quantum computing. However, profitability remains a concern. Non-GAAP net loss widened to $16 million from $13.3 million a year ago, while operating loss increased to $28.1 million. Higher research and development and selling, general and administrative expenses continued to weigh on results. Rigetti also faces the technical challenge of improving coherence and fidelity as systems scale to higher qubit counts. The Department ", "date_published": "2026-08-07T17:55:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "MCK"], "_sharemaestro": {"country": "Mexico", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MCK", "name": "McKesson Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/0690fb95-d935-4df1-aa4f-b67259d735cf/"}]}}, {"id": "source:bd73e7155e9dfc4812aa5fe4d253f8ce715d3dbc402549c0f5f85ae7a8546c7e", "url": "https://news.google.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?oc=5", "external_url": "https://news.google.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?oc=5", "title": "\u00bfEst\u00e1 el crecimiento de los ingresos de McKesson, junto con la ca\u00edda del beneficio por acci\u00f3n, alterando el argumento de inversi\u00f3n a favor de McKesson (MCK)?", "content_text": "\u00bfEst\u00e1 el crecimiento de los ingresos de McKesson, junto con la ca\u00edda del beneficio por acci\u00f3n, alterando el argumento de inversi\u00f3n a favor de McKesson (MCK)?", "date_published": "2026-08-06T07:00:00+00:00", "authors": [{"name": "simplywall.st"}], "tags": ["Market update", "MCK"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MCK", "name": "McKesson Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/0690fb95-d935-4df1-aa4f-b67259d735cf/"}]}}, {"id": "source:ca76b7f0d0dff2e92061d222f8e22bcdfaa1a506ceb938dbec1dc61e53117f63", "url": "https://news.google.com/rss/articles/CBMi-gFBVV95cUxNWmo0SEFLeGVZaW1mOXFRa2ZXemg4Um9kZjJCUVlXOFlJR1JQYTZRTWw4YXBCeFNaWmFwYnlCZ2t6SEl3Y256cGtZQXZDbVBULWFzYzZvanMtSTBnZ1hMbE1vYlkySTlsTllQR0ZpQmdBWjBjd3h5TVVoTDBfU3JGX1JySzRDWTczYXdkNXc4Y25QNVRrS24wQWd2aFpsNV90c090UkUxS2xHV2tZX2l5QWFDX2tlU25nRXZCay1fMV96dEtrYTFJMVN4TFpCVVlnd0NfZE9JTjNmRzcyXzM4b0h6UUN5Z3I0RUU1MU40NVN4OGJ0cHdaV3h3?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi-gFBVV95cUxNWmo0SEFLeGVZaW1mOXFRa2ZXemg4Um9kZjJCUVlXOFlJR1JQYTZRTWw4YXBCeFNaWmFwYnlCZ2t6SEl3Y256cGtZQXZDbVBULWFzYzZvanMtSTBnZ1hMbE1vYlkySTlsTllQR0ZpQmdBWjBjd3h5TVVoTDBfU3JGX1JySzRDWTczYXdkNXc4Y25QNVRrS24wQWd2aFpsNV90c090UkUxS2xHV2tZX2l5QWFDX2tlU25nRXZCay1fMV96dEtrYTFJMVN4TFpCVVlnd0NfZE9JTjNmRzcyXzM4b0h6UUN5Z3I0RUU1MU40NVN4OGJ0cHdaV3h3?oc=5", "title": "Informe de resultados de McKesson: supera las estimativas del primer trimestre de 2027 y mejora sus perspectivas", "content_text": "Informe de resultados de McKesson: supera las estimativas del primer trimestre de 2027 y mejora sus perspectivas", "date_published": "2026-08-05T22:17:00+00:00", "authors": [{"name": "Investing.com Espa\u00f1a"}], "tags": ["Market update", "MCK"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MCK", "name": "McKesson Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/0690fb95-d935-4df1-aa4f-b67259d735cf/"}]}}]}